Our priority is identifying, researching, and developing treatment options that will create a lasting impact for patients around the world. AlphaMeld is deployed for a number of drug discovery initiatives across multiple modalities and for diseases that lack transformative treatment options.
| Therapeutic Area | Company | Asset | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|
| NEUROSCIENCE IMMUNO-ONCOLOGY |
|
BXCL501 BXCL701 |
||||
| MULTIPLE THERAPEUTIC AREAS |
|
Proprietary Proprietary |
||||
| PAIN |
|
CNTX-6970 CNTX-6016 CNTX-0290 |
||||
| INFLAMMATORY GUT DISORDERS |
|
Proprietary | ||||
| INFECTIOUS DISEASES |
|
Proprietary Proprietary |
||||
We are witnessing a paradigm shift as technology empowers consumers who are involved, engaged, and taking control of their health by seeking products and services that create meaningful value for their day-to-day experiences. This presents a critical need to develop insights from numerous data sources that allow our collaborators to stay ahead of the curve by identifying consumer-specific innovation and converting the earliest signals of discovery into innovative products for their consumers.
We are partners with GSK and are proud to be executing a three-year collaboration with one of the largest consumer healthcare companies in the world. The collaboration leverages AlphaMeld® technology to capture consumer-specific innovation for both internal and external R&D.
Copyright 2023 InveniAI LLC.
All Rights Reserved
